Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
52
BIOA Quote, Financials, Valuation and Earnings
Last price:
$12.57
Seasonality move
:
-74.67%
Day range:
$12.55 - $13.06
52-week range:
$2.88 - $13.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
78.04x
P/B ratio:
1.66x
Volume:
327.7K
Avg. volume:
377.6K
1-year change:
180.61%
Market cap:
$461.8M
Revenue:
--
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingBioAge Labs, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $12.00, BioAge Labs, Inc. has an estimated downside of -6.83% from its current price of $12.88.
-
Price Target UpsideAccording to analysts, the highest upside price target is $15.00 representing -100% upside increase from its current price of $12.88.
Fair Value
-
According to the consensus of 4 analysts, BioAge Labs, Inc. has -6.83% downside to fair value with a price target of $12.00 per share.
BIOA vs. S&P 500
-
Over the past 5 trading days, BioAge Labs, Inc. has overperformed the S&P 500 by 11.64% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioAge Labs, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioAge Labs, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioAge Labs, Inc. reported revenues of $2.1M.
Earnings Growth
-
BioAge Labs, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioAge Labs, Inc. reported earnings per share of -$0.56.
Enterprise value:
183.2M
EV / Invested capital:
0.64x
Price / LTM sales:
78.04x
EV / EBIT:
--
EV / Revenue:
30.96x
PEG ratio (5yr expected):
-0.51x
EV / Free cash flow:
-3.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.7M
Return On Assets:
-22.74%
Net Income Margin (TTM):
-1280.9%
Return On Equity:
-24.89%
Return On Invested Capital:
-24.18%
Operating Margin:
-1126.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $5.9M | -- | $2.1M | |
| Gross Profit | -$121K | -$168K | $5.7M | -$38K | $2M | |
| Operating Income | -- | -$62.7M | -$89.7M | -$24.8M | -$23.1M | |
| EBITDA | -- | -$62.6M | -$89.5M | -$24.7M | -$23.1M | |
| Diluted EPS | -$1.26 | -$1.89 | -$2.11 | -$0.68 | -$0.56 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $336.5M | $290.8M | |
| Total Assets | -- | -- | -- | $337.4M | $305.1M | |
| Current Liabilities | -- | -- | -- | $19.1M | $24.5M | |
| Total Liabilities | -- | -- | -- | $23.6M | $27.6M | |
| Total Equity | -- | -- | -- | $313.7M | $277.5M | |
| Total Debt | -- | -- | -- | $9.9M | $6.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$54.9M | -$58.5M | -$14.9M | -$16M | |
| Cash From Investing | -- | -$340K | -$80.8M | -$305K | $12.8M | |
| Cash From Financing | -- | $355.3M | $20.4M | $190.7M | -$1.5M | |
| Free Cash Flow | -- | -$55.2M | -$59.1M | -$15.2M | -$16.1M | |
BIOA
Sector
Market Cap
$461.8M
$29M
Price % of 52-Week High
98.32%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-12.07%
-1.4%
1-Year Price Total Return
180.61%
-19%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.69
200-day SMA
Buy
Level
$5.27
Bollinger Bands (100)
Buy
Level
4.17 - 8.55
Chaikin Money Flow
Sell
Level
-5M
20-day SMA
Buy
Level
$9.89
Relative Strength Index (RSI14)
Buy
Level
83.00
ADX Line
Buy
Level
47.45
Williams %R
Sell
Level
-4.7414
50-day SMA
Buy
Level
$7.94
MACD (12, 26)
Buy
Level
1.36
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
14M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9364)
Sell
CA Score
(Annual)
Level (-1.2213)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.8645)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, BIOA has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BIOA average analyst price target in the past 3 months is $12.00.
-
Where Will BioAge Labs, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioAge Labs, Inc. share price will drop to $12.00 per share over the next 12 months.
-
What Do Analysts Say About BioAge Labs, Inc.?
Analysts are divided on their view about BioAge Labs, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioAge Labs, Inc. is a Sell and believe this share price will rise from its current level to $9.00.
-
What Is BioAge Labs, Inc.'s Price Target?
The price target for BioAge Labs, Inc. over the next 1-year time period is forecast to be $12.00 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BIOA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioAge Labs, Inc. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIOA?
You can purchase shares of BioAge Labs, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioAge Labs, Inc. shares.
-
What Is The BioAge Labs, Inc. Share Price Today?
BioAge Labs, Inc. was last trading at $12.57 per share. This represents the most recent stock quote for BioAge Labs, Inc.. Yesterday, BioAge Labs, Inc. closed at $12.88 per share.
-
How To Buy BioAge Labs, Inc. Stock Online?
In order to purchase BioAge Labs, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIOA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIOA
Sector
P/E ratio
--
24.19x
PEG ratio
-0.51x
-0.01x
P/B ratio
1.66x
1.84x
Price / LTM sales
78.04x
1.61x
Growth Metrics
BIOA
Sector
Revenue growth
--
4.6%
Earnings growth
17.81%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.51
-$0.20
Profitability
BIOA
Sector
Profitability FY 2024
-$167K
$3.5M
Return on invested capital
-24.18%
-31.66%
Return on assets
-22.74%
-27.84%
Return on equity
-24.89%
-37.15%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
5
Balance Sheet
BIOA
Sector
Total cash
$285.8M
$26.8M
Short term investments
--
$26M
Total assets
$358.3M
$79.7M
Long term debt
$6.6M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.13% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.57% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.39% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
